Fieldview Capital Management LLC Purchases Shares of 14,272 Biogen Inc. $BIIB

Fieldview Capital Management LLC purchased a new stake in shares of Biogen Inc. (NASDAQ:BIIB) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 14,272 shares of the biotechnology company’s stock, valued at approximately $2,512,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. WPG Advisers LLC boosted its stake in Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 117 shares in the last quarter. Accredited Wealth Management LLC boosted its stake in Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 185 shares in the last quarter. First Horizon Corp bought a new position in Biogen during the 4th quarter valued at $30,000. WFA of San Diego LLC bought a new position in Biogen during the 2nd quarter valued at $32,000. Finally, Root Financial Partners LLC boosted its stake in Biogen by 198.4% during the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 123 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Morgan Stanley increased their price target on Biogen from $200.00 to $206.00 and gave the company an “equal weight” rating in a research note on Thursday, April 30th. Oppenheimer increased their price objective on Biogen from $275.00 to $300.00 and gave the company an “outperform” rating in a research report on Thursday, May 14th. Evercore started coverage on Biogen in a research report on Friday, May 15th. They set an “outperform” rating for the company. Argus upgraded Biogen to a “hold” rating in a research report on Thursday, April 9th. Finally, HSBC increased their price objective on Biogen from $143.00 to $150.00 and gave the company a “reduce” rating in a research report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $217.26.

Biogen Price Performance

Shares of NASDAQ:BIIB opened at $200.05 on Friday. Biogen Inc. has a one year low of $121.05 and a one year high of $205.97. The stock has a fifty day moving average of $188.73 and a 200-day moving average of $184.31. The company has a market capitalization of $29.54 billion, a PE ratio of 21.46 and a beta of 0.20. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the prior year, the firm earned $3.02 EPS. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities analysts anticipate that Biogen Inc. will post 14.18 EPS for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.